' 
SCIENTIFIC SCORE
Most Likely Effective
Based on 32 Researches
7.3
USERS' SCORE
Very Good
Based on 19 Reviews
7.9
Supplement Facts
Serving Size: 1 Softgel
Amount Per Serving
%DV
Calories
10
Total Fat
1 g
1%**
Saturated Fat
< 0.5 g
2%**
Polyunsaturated Fat
0.5 g
†
Fish Oil Concentrate
1 g (1,000 mg)
†
Omega-3 Fatty Acids:
Eicosapentaenoic Acid (EPA)
180 mg
†
Docosahexaenoic Acid (DHA)
120 mg
†
Top Medical Research Studies
9
Omega-3 lowers coronary risk
A Bayesian Analysis of the VITAL Trial: Effects of Omega-3 Fatty Acid Supplementation on Cardiovascular Events.
Directly related to heart disease
We explored the impact of eicosapentaenoic acid (EPA), a type of omega-3 fatty acid, on heart disease through a significant study known as the VITAL trial. This study involved nearly 26,000 older adults in the U.S. and aimed to determine the effects of daily EPA supplementation on cardiovascular events over an average follow-up of 5.3 years.
Initially, the results from VITAL seemed to show that omega-3 supplementation had no significant effect on major cardiovascular disease (CVD) events. However, by applying Bayesian methods and considering prior research in the field, we observed a more nuanced outcome. Our analysis suggested that taking EPA regularly could significantly reduce the risk of coronary heart disease events, while not showing similar benefits for stroke.
This finding supports the use of omega-3 fatty acids as a preventive measure for heart health, especially regarding coronary events. Although we didn't find evidence of a benefit for all types of cardiovascular events, the enhanced understanding gained from this reanalysis contributes valuable insights for both clinicians and patients considering omega-3 supplementation for heart disease prevention.
Initially, the results from VITAL seemed to show that omega-3 supplementation had no significant effect on major cardiovascular disease (CVD) events. However, by applying Bayesian methods and considering prior research in the field, we observed a more nuanced outcome. Our analysis suggested that taking EPA regularly could significantly reduce the risk of coronary heart disease events, while not showing similar benefits for stroke.
This finding supports the use of omega-3 fatty acids as a preventive measure for heart health, especially regarding coronary events. Although we didn't find evidence of a benefit for all types of cardiovascular events, the enhanced understanding gained from this reanalysis contributes valuable insights for both clinicians and patients considering omega-3 supplementation for heart disease prevention.
Read More
9
EPA helps fight heart disease
Eicosapentaenoic acid induces macrophage Mox polarization to prevent diabetic cardiomyopathy.
Strong evidence of EPA's benefits
We explored the effects of eicosapentaenoic acid (EPA) on heart disease, particularly diabetic cardiomyopathy (DC). This condition is a significant cause of heart failure, yet until now, effective treatment options have been limited. Our study focused on the protective role of EPA in diabetic mice induced by streptozotocin and high-fat diets.
Our findings indicate that EPA is beneficial in reducing the harmful M1-polarized macrophages in the heart. In laboratory tests, EPA showed the ability to protect heart cells from damage caused by these inflammatory cells by shifting the macrophage type from M1 to Mox, rather than to the M2 type. This is crucial since Mox polarization can help shield heart cells from the adverse effects of M1 macrophages.
Additionally, we discovered that a protein called heme oxygenase 1 (HO-1) plays a crucial role in sustaining this protective Mox phenotype. EPA promotes HO-1 levels, which in turn helps reduce M1 polarization and its damaging effects on heart cells. Even more promising, EPA was shown to enhance Mox polarization in macrophages derived from diabetic patients, indicating its potential as a treatment strategy.
Overall, our research highlights EPA and macrophage Mox polarization as innovative approaches to combat diabetic cardiomyopathy, showcasing a new avenue in the fight against heart disease.
Our findings indicate that EPA is beneficial in reducing the harmful M1-polarized macrophages in the heart. In laboratory tests, EPA showed the ability to protect heart cells from damage caused by these inflammatory cells by shifting the macrophage type from M1 to Mox, rather than to the M2 type. This is crucial since Mox polarization can help shield heart cells from the adverse effects of M1 macrophages.
Additionally, we discovered that a protein called heme oxygenase 1 (HO-1) plays a crucial role in sustaining this protective Mox phenotype. EPA promotes HO-1 levels, which in turn helps reduce M1 polarization and its damaging effects on heart cells. Even more promising, EPA was shown to enhance Mox polarization in macrophages derived from diabetic patients, indicating its potential as a treatment strategy.
Overall, our research highlights EPA and macrophage Mox polarization as innovative approaches to combat diabetic cardiomyopathy, showcasing a new avenue in the fight against heart disease.
Read More
8
Eicosapentaenoic Acid reduces heart risks
Omega-3 Fatty Acids as Potential Predictors of Sudden Cardiac Death and Cardiovascular Mortality: A Systematic Review and Meta-Analysis.
High relevance to heart health
We evaluated the impact of eicosapentaenoic acid (EPA) on heart disease, specifically focusing on its potential to reduce the risk of sudden cardiac death (SCD) and cardiovascular mortality (CVD mortality). Through a systematic review and meta-analysis, we gathered insights from 10 prospective cohort studies involving a total of 310,955 participants over an average follow-up period of 8.7 years.
Our analysis revealed that higher levels of omega-3 fatty acids, including EPA, in the blood were associated with a lower risk of both SCD and CVD mortality. Specifically, we found that individuals with high circulating levels of EPA and other omega-3s had a significantly reduced hazard ratio of 0.55 for SCD compared to those with lower levels. This suggests a protective effect linked to increased EPA intake.
Furthermore, our sub-analysis indicated that higher percentages of EPA and another omega-3 called DHA in the blood also correlated with a reduced risk of adverse cardiac events. These findings highlight the promising role of EPA as a beneficial component in cardiovascular health strategies.
Overall, the evidence suggests that increasing our intake of EPA could serve as an effective measure to lessen the incidence of serious heart-related issues, making it a topic worth considering in future dietary recommendations.
Our analysis revealed that higher levels of omega-3 fatty acids, including EPA, in the blood were associated with a lower risk of both SCD and CVD mortality. Specifically, we found that individuals with high circulating levels of EPA and other omega-3s had a significantly reduced hazard ratio of 0.55 for SCD compared to those with lower levels. This suggests a protective effect linked to increased EPA intake.
Furthermore, our sub-analysis indicated that higher percentages of EPA and another omega-3 called DHA in the blood also correlated with a reduced risk of adverse cardiac events. These findings highlight the promising role of EPA as a beneficial component in cardiovascular health strategies.
Overall, the evidence suggests that increasing our intake of EPA could serve as an effective measure to lessen the incidence of serious heart-related issues, making it a topic worth considering in future dietary recommendations.
Read More
Most Useful Reviews
7.5
Improves heart rhythm
These capsules are huge, which was surprising, but the taste is minimal. Since taking them, I've felt a marked improvement in my heart condition and rhythm.
Read More
8.3
No fishy taste
I appreciate the good price and concentration of this product. It’s halal and odourless, making it easy to consume, and it's effective for heart health.
Read More
8.3
Promotes heart health
NOW Foods Omega-3 provides 1000 mg per softgel with targeted EPA and DHA doses. It has an enteric coating that removes any fishy aftertaste, making it excellent for heart health and cognitive function.
Read More
Most Recommended Products for Heart Disease
Solgar L-Lysine
SCIENTIFIC SCORE
No researches found
N/A
USERS' SCORE
Excellent
Based on 1 Reviews
9.5
Tums Ultra Strength Antacid
SCIENTIFIC SCORE
No researches found
N/A
USERS' SCORE
Excellent
Based on 1 Reviews
9.5
American Health Ester-C with Citrus Bioflavonoids
SCIENTIFIC SCORE
No researches found
N/A
USERS' SCORE
Excellent
Based on 1 Reviews
9.5
Medical Researches
SCIENTIFIC SCORE
Most Likely Effective
Based on 32 Researches
7.3
9
Omega-3 lowers coronary risk
A Bayesian Analysis of the VITAL Trial: Effects of Omega-3 Fatty Acid Supplementation on Cardiovascular Events.
Directly related to heart disease
We explored the impact of eicosapentaenoic acid (EPA), a type of omega-3 fatty acid, on heart disease through a significant study known as the VITAL trial. This study involved nearly 26,000 older adults in the U.S. and aimed to determine the effects of daily EPA supplementation on cardiovascular events over an average follow-up of 5.3 years.
Initially, the results from VITAL seemed to show that omega-3 supplementation had no significant effect on major cardiovascular disease (CVD) events. However, by applying Bayesian methods and considering prior research in the field, we observed a more nuanced outcome. Our analysis suggested that taking EPA regularly could significantly reduce the risk of coronary heart disease events, while not showing similar benefits for stroke.
This finding supports the use of omega-3 fatty acids as a preventive measure for heart health, especially regarding coronary events. Although we didn't find evidence of a benefit for all types of cardiovascular events, the enhanced understanding gained from this reanalysis contributes valuable insights for both clinicians and patients considering omega-3 supplementation for heart disease prevention.
Initially, the results from VITAL seemed to show that omega-3 supplementation had no significant effect on major cardiovascular disease (CVD) events. However, by applying Bayesian methods and considering prior research in the field, we observed a more nuanced outcome. Our analysis suggested that taking EPA regularly could significantly reduce the risk of coronary heart disease events, while not showing similar benefits for stroke.
This finding supports the use of omega-3 fatty acids as a preventive measure for heart health, especially regarding coronary events. Although we didn't find evidence of a benefit for all types of cardiovascular events, the enhanced understanding gained from this reanalysis contributes valuable insights for both clinicians and patients considering omega-3 supplementation for heart disease prevention.
Read More
9
Eicosapentaenoic acid improves heart function
The Optimal Dosage and Duration of ω-3 PUFA Supplementation in Heart Failure Management: Evidence from a Network Meta-Analysis.
Directly studies heart failure treatment
We explored how eicosapentaenoic acid (a type of omega-3 fatty acid) can play a role in improving heart health, particularly in individuals with heart failure. Our analysis involved a network meta-analysis of numerous randomized controlled trials, focusing on the effects of eicosapentaenoic acid on heart function.
The findings showed that high doses of omega-3 supplements, specifically between 2000 to 4000 mg per day, taken for at least a year, can significantly enhance left ventricular ejection fraction, which is an important measure of heart function. This is encouraging news for patients struggling with heart failure, as a better ejection fraction can lead to improved heart health.
We also observed improvements in peak oxygen consumption, offering further evidence of how eicosapentaenoic acid can boost cardiac performance. Importantly, we found no significant increases in dropout rates or overall mortality among those taking omega-3 supplements compared to those not taking them. This suggests that the benefits come without added risks.
Overall, our research underscores the potential of long-term, high-dose eicosapentaenoic acid supplementation as a supportive treatment option for heart failure patients, advocating for further studies to confirm these promising results and help refine treatment recommendations.
The findings showed that high doses of omega-3 supplements, specifically between 2000 to 4000 mg per day, taken for at least a year, can significantly enhance left ventricular ejection fraction, which is an important measure of heart function. This is encouraging news for patients struggling with heart failure, as a better ejection fraction can lead to improved heart health.
We also observed improvements in peak oxygen consumption, offering further evidence of how eicosapentaenoic acid can boost cardiac performance. Importantly, we found no significant increases in dropout rates or overall mortality among those taking omega-3 supplements compared to those not taking them. This suggests that the benefits come without added risks.
Overall, our research underscores the potential of long-term, high-dose eicosapentaenoic acid supplementation as a supportive treatment option for heart failure patients, advocating for further studies to confirm these promising results and help refine treatment recommendations.
Read More
9
EPA helps fight heart disease
Eicosapentaenoic acid induces macrophage Mox polarization to prevent diabetic cardiomyopathy.
Strong evidence of EPA's benefits
We explored the effects of eicosapentaenoic acid (EPA) on heart disease, particularly diabetic cardiomyopathy (DC). This condition is a significant cause of heart failure, yet until now, effective treatment options have been limited. Our study focused on the protective role of EPA in diabetic mice induced by streptozotocin and high-fat diets.
Our findings indicate that EPA is beneficial in reducing the harmful M1-polarized macrophages in the heart. In laboratory tests, EPA showed the ability to protect heart cells from damage caused by these inflammatory cells by shifting the macrophage type from M1 to Mox, rather than to the M2 type. This is crucial since Mox polarization can help shield heart cells from the adverse effects of M1 macrophages.
Additionally, we discovered that a protein called heme oxygenase 1 (HO-1) plays a crucial role in sustaining this protective Mox phenotype. EPA promotes HO-1 levels, which in turn helps reduce M1 polarization and its damaging effects on heart cells. Even more promising, EPA was shown to enhance Mox polarization in macrophages derived from diabetic patients, indicating its potential as a treatment strategy.
Overall, our research highlights EPA and macrophage Mox polarization as innovative approaches to combat diabetic cardiomyopathy, showcasing a new avenue in the fight against heart disease.
Our findings indicate that EPA is beneficial in reducing the harmful M1-polarized macrophages in the heart. In laboratory tests, EPA showed the ability to protect heart cells from damage caused by these inflammatory cells by shifting the macrophage type from M1 to Mox, rather than to the M2 type. This is crucial since Mox polarization can help shield heart cells from the adverse effects of M1 macrophages.
Additionally, we discovered that a protein called heme oxygenase 1 (HO-1) plays a crucial role in sustaining this protective Mox phenotype. EPA promotes HO-1 levels, which in turn helps reduce M1 polarization and its damaging effects on heart cells. Even more promising, EPA was shown to enhance Mox polarization in macrophages derived from diabetic patients, indicating its potential as a treatment strategy.
Overall, our research highlights EPA and macrophage Mox polarization as innovative approaches to combat diabetic cardiomyopathy, showcasing a new avenue in the fight against heart disease.
Read More
9
Omega-3s and heart disease risk
Circulating Omega-3 Polyunsaturated Fatty Acids Levels in Coronary Heart Disease: Pooled Analysis of 36 Observational Studies.
Considered broader omega-3 impacts
We explored the connection between omega-3 fatty acids, particularly eicosapentaenoic acid (EPA), and coronary heart disease (CHD). Our analysis reviewed 36 observational studies that included both prospective and retrospective designs, offering a well-rounded look at how different omega-3 levels may impact heart health.
The results highlighted a clear trend: higher levels of various omega-3 fatty acids, including EPA, were associated with a reduced risk of developing CHD. We noted that groups with elevated omega-3 levels displayed lower relative risks—indicating that maintaining a sufficient intake of these fatty acids could be beneficial for heart health.
Interestingly, our findings revealed that patients with CHD had significantly lower omega-3 levels compared to healthier individuals. Moreover, specific subtypes of omega-3, such as EPA and DHA, demonstrated a particularly strong inverse relationship with both fatal and non-fatal heart disease events.
Overall, this analysis shows that omega-3 polyunsaturated fatty acids, especially EPA and DHA, are linked to a decreased risk of CHD. Our findings support the idea that integrating these nutrients into our diets may provide protective benefits against heart disease.
The results highlighted a clear trend: higher levels of various omega-3 fatty acids, including EPA, were associated with a reduced risk of developing CHD. We noted that groups with elevated omega-3 levels displayed lower relative risks—indicating that maintaining a sufficient intake of these fatty acids could be beneficial for heart health.
Interestingly, our findings revealed that patients with CHD had significantly lower omega-3 levels compared to healthier individuals. Moreover, specific subtypes of omega-3, such as EPA and DHA, demonstrated a particularly strong inverse relationship with both fatal and non-fatal heart disease events.
Overall, this analysis shows that omega-3 polyunsaturated fatty acids, especially EPA and DHA, are linked to a decreased risk of CHD. Our findings support the idea that integrating these nutrients into our diets may provide protective benefits against heart disease.
Read More
9
Docosahexaenoic acid benefits heart health
The Optimal Dosage and Duration of ω-3 PUFA Supplementation in Heart Failure Management: Evidence from a Network Meta-Analysis.
Moderate relevance for DHA impact
We aimed to understand how docosahexaenoic acid (DHA), a form of omega-3 polyunsaturated fatty acid (PUFA), could benefit patients suffering from heart failure. Our investigation drew on a network meta-analysis that included data from 14 randomized controlled trials, comprising 9,075 participants. This analysis focused particularly on the effects of DHA and other omega-3s on heart health metrics.
The findings revealed that high doses of omega-3 PUFA supplementation, specifically between 2000 to 4000 mg daily for at least one year, significantly improved heart function. We observed notable enhancements in the left ventricular ejection fraction and peak oxygen consumption, crucial indicators of heart performance, when compared to control groups.
Interestingly, lower doses and shorter periods of supplementation did not yield the same positive results. Importantly, we found no significant increase in dropout rates or overall mortality among those taking omega-3 PUFAs compared to those who were not. This suggests that high-dose DHA supplementation can enhance cardiac function without raising safety concerns.
Overall, our research indicates that long-term, high-dose DHA can be a beneficial strategy in managing heart failure. However, we recognize that further well-designed trials with stringent criteria are needed to validate these findings fully.
The findings revealed that high doses of omega-3 PUFA supplementation, specifically between 2000 to 4000 mg daily for at least one year, significantly improved heart function. We observed notable enhancements in the left ventricular ejection fraction and peak oxygen consumption, crucial indicators of heart performance, when compared to control groups.
Interestingly, lower doses and shorter periods of supplementation did not yield the same positive results. Importantly, we found no significant increase in dropout rates or overall mortality among those taking omega-3 PUFAs compared to those who were not. This suggests that high-dose DHA supplementation can enhance cardiac function without raising safety concerns.
Overall, our research indicates that long-term, high-dose DHA can be a beneficial strategy in managing heart failure. However, we recognize that further well-designed trials with stringent criteria are needed to validate these findings fully.
Read More
User Reviews
USERS' SCORE
Very Good
Based on 19 Reviews
7.9
9.5
Improves heart condition
I have been purchasing this product for a long time. It’s high in omega-3 and good for heart health and hair. The taste is neutral, and it positively affects cholesterol levels, helping prevent inflammation.
9.5
Reduces inflammation
Omega 3 effectively lowers the risk of heart disease and arthritis by minimising inflammation. The capsule size is average, and the quality is excellent.
9
Enhances heart vitality
This fish oil is high quality and beneficial for both adults and children. The packaging lasts about three months. It strengthens hair and bones while promoting heart health and reducing inflammation. The taste is negligible when swallowed.
9
Supports heart health
Fish oil is effective for lowering cholesterol and supporting heart health. The quality is very good and the concentration is relatively high.
8.8
Supports heart health
Omega 3 is essential for reducing cholesterol and inflammation, which aids in preventing heart disease. It’s suitable for those who rarely consume fish, and the quality is excellent. The capsules have a mild fish taste, but the packaging is securely sealed.
